E2F1

Summary

E2F1 (E2F transcription factor 1, HGNC:3113) is a protein-coding gene on chromosome 20q11.22, encoding Transcription factor E2F1 (Q01094). Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5’-TTTC[CG]CGC-3’ found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. It is a selective cancer dependency (DepMap: 15.8% of cell lines).

The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members, E2F2 and E2F3, have an additional cyclin binding domain. This protein binds preferentially to retinoblastoma protein pRB in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent/independent apoptosis.

Source: NCBI Gene 1869 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 57 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 15.8% of screened cell lines
• Transcription factor: yes — 493 downstream targets (CollecTRI)
• MANE Select transcript: NM_005225

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3113
Approved symbol	E2F1
Name	E2F transcription factor 1
Location	20q11.22
Locus type	gene with protein product
Status	Approved
Aliases	RBP3
Ensembl gene	ENSG00000101412
Ensembl biotype	protein_coding
OMIM	189971
Entrez	1869

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000343380, ENST00000888354, ENST00000932103, ENST00000932104

RefSeq mRNA: 1 — MANE Select: NM_005225 NM_005225

CCDS: CCDS13224

Canonical transcript exons

ENST00000343380 — 7 exons

Exon	Start	End
ENSE00000661342	33677105	33677330
ENSE00000661345	33679755	33679974
ENSE00000661346	33680326	33680416
ENSE00000860058	33677426	33677540
ENSE00001386402	33675477	33676979
ENSE00001387594	33678201	33678353
ENSE00001667355	33686004	33686385

Expression profiles

Bgee: expression breadth ubiquitous, 193 present calls, max score 89.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.6683 / max 413.5667, expressed in 1440 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
186970	12.6683	1440

Top tissues by expression

267 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	89.40	gold quality
secondary oocyte	CL:0000655	89.18	gold quality
ventricular zone	UBERON:0003053	88.37	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.60	gold quality
oocyte	CL:0000023	85.01	gold quality
embryo	UBERON:0000922	83.65	gold quality
endometrium epithelium	UBERON:0004811	83.59	gold quality
mucosa of transverse colon	UBERON:0004991	80.76	gold quality
stromal cell of endometrium	CL:0002255	79.72	gold quality
olfactory bulb	UBERON:0002264	78.62	gold quality
type B pancreatic cell	CL:0000169	78.39	gold quality
prefrontal cortex	UBERON:0000451	78.08	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.87	gold quality
bone marrow	UBERON:0002371	77.69	gold quality
tendon of biceps brachii	UBERON:0008188	77.64	gold quality
lower esophagus mucosa	UBERON:0035834	77.18	gold quality
putamen	UBERON:0001874	75.47	gold quality
male germ cell	CL:0000015	75.28	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	75.23	gold quality
vena cava	UBERON:0004087	75.17	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	75.06	gold quality
triceps brachii	UBERON:0001509	74.98	gold quality
lymph node	UBERON:0000029	74.95	gold quality
right adrenal gland cortex	UBERON:0035827	74.82	gold quality
sperm	CL:0000019	74.78	gold quality
frontal cortex	UBERON:0001870	74.54	gold quality
cervix squamous epithelium	UBERON:0006922	74.53	gold quality
gluteal muscle	UBERON:0002000	74.52	gold quality
right adrenal gland	UBERON:0001233	74.45	gold quality
right testis	UBERON:0004534	74.42	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-10662	yes	109.44
E-ANND-3	no	2.68

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

493 targets.

Target	Regulation
ABCA1	Unknown
ABCB1	Activation
ABCG2	Unknown
ACAN	Repression
ACSL1	Unknown
ACTR2	Unknown
ADAM2
ADH6	Unknown
AK3	Unknown
ALG5
ALOX5AP	Unknown
AMPD3	Unknown
ANGPT2	Activation
ANKRD16	Unknown
APAF1	Activation
AR	Activation
ARHGEF17	Unknown
ARL10	Unknown
ARMC8	Unknown
ASCC2	Unknown
ASF1B	Activation
ATAD2	Unknown
ATG10	Activation
ATG12	Activation
ATG4A	Activation
ATG4B	Activation
ATG4D	Activation
ATG5	Activation
ATG7	Activation
ATG9A	Activation

JASPAR motifs

Motif	Name	Family
MA0024.1	E2F1	E2F
MA0024.2	E2F1	E2F
MA0024.3	E2F1	E2F

JASPAR matrix evidence (PMIDs): PMID:1411535, PMID:17908821, PMID:9372931

Upstream regulators (CollecTRI, top): ARID3A, ATM, CTNNB1, E2F1, E2F2, E2F3, E2F4, E2F5, E2F6, E2F7, E2F8, ELL, ERCC2, ESR1, FOS, FOXC1, FOXJ3, GLI2, HCFC1, HDAC1, HES1, HES6, HIC1, IRF1, KLF15, KMT2E, LEF1, MECOM, MYBL2, MYC, MYOD1, NANOG, NFKB1, NFKB, NFYA, NKX2-5, NKX6-1, NR0B2, NR2F2, NR4A1

miRNA regulators (miRDB)

66 targeting E2F1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868
HSA-MIR-519C-3P	99.67	71.67	1870
HSA-MIR-6887-3P	99.66	67.83	1778

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 15.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• transcriptional inhibition of the plasminogen activator inhibitor type 1 gene (PMID:11559366)
• expression reduced in primary and metastatic breast carcinoma (PMID:11759817)
• selection and characterization of active hammerhead ribozymes targeted against E2F1 full-length mRNA (PMID:11763345)
• Regulation of E2F1-dependent gene transcription and apoptosis by the ETS-related transcription factor GABPgamma1 (PMID:11884602)
• increased ppRb and E2FI immunoreactivity in Alzheimer disease brain, with ppRb predominately located in the nucleus and E2F1 in the cytoplasm. (PMID:11939591)
• Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway. (PMID:12032846)
• Overexpression of E2F-1 induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Cell cycle, PARP cleavage and morphology supported apoptosis as the cell death mechanism in reponse to E2F1. (PMID:12065845)
• conclude that E2F proteins and Sp1 play an important role in the control of p18 expression (PMID:12077144)
• p14(ARF) regulates E2F activity in different cell types and down-regulates E2F-dependent transcription, and in cells undergoing E2F-dependent apoptosis prompts cell cycle arrest. p14(ARF) possesses multiple binding domains for E2F-1. (PMID:12082609)
• p73beta is transcriptionally induced by E2F-1 and functions as a positive regulator of apoptosis. (PMID:12095638)
• Most of the TGF-beta1-induced preapoptotic cells were arrested in G(1) phase of the cell cycle. This was associated with a significant increase in both E2F-DNA-binding activity and transcription of E2F-responsive reporter constructs. (PMID:12118073)
• E2F-1 regulates the expression of APAF-1 in human cells (PMID:12149244)
• E2F-1 has a role in regulation of caspase proenzymes through a direct transcriptional mechanism (PMID:12389032)
• Che-1 contacts the pocket region of Rb and removes HDAC1 from the Rb/E2F1 complex, affecting the activation of E2F-dependent promoters and cell division. (PMID:12450794)
• During thyroid hormone-induced differentiation of embryonic carcinoma cells and of oligodendrocyte precursor cells, levels of E2F-1 mRNA and E2F-1 protein decrease, caused by thyroid hormone receptor regulating the transcription of the E2F-1 gene. (PMID:12511608)
• IFN-gamma is an effective inhibitor of ASM cell proliferation by blocking transition from G1-to-S phase by acting at two different levels: modulation of cdk2/cyclin E activation and inhibition of E2F-1 gene expression. (PMID:12588705)
• expression of the transcription factor DP-1 and its heterodimeric partner E2F-1 in non-Hodgkin lymphoma (PMID:12607600)
• We found that E2F1 was present at most of the CpG islands bound by pRb, independent of the phase of the cell cycle, our data suggest that the majority of DNA-bound pRb is recruited to E2F target promoters during both G(0)/G(1) and S phases. (PMID:12629508)
• P202 inhibits E2F1-mediated apoptosis in prostate cancer cells (PMID:12646190)
• E2F1 is involved in heat shock-induced cell cycle arrests at the G1/S and G2/M checkpoints, which also may be relevant for hyperthermic cancer therapy (PMID:12674510)
• esf-1 induces apoptosis and inhibits proliferation of human colon cancer cell lines; a caspase-independent pathway is suggested (PMID:12679318)
• Chk2 phosphorylates and activates E2F-1 in response to DNA damage, resulting in apoptosis. This suggests a role for E2F-1 in checkpoint control and tumour suppression. (PMID:12717439)
• In response to DNA damage, E2F1 is directed from cell cycle progression to apoptotic E2F target genes. (PMID:12766778)
• Analysis of gene expression level profiles showed that parental cell line undergoes apoptosis through an E2F1/p73-dependent pathway while its drug resistant variant evades it. (PMID:12789260)
• Both senescence-associated heterochromatin foci formation and the silencing of E2F target genes depend on the integrity of the Rb pathway and do not occur in reversibly arrested cells (PMID:12809602)
• C/EBPepsilon interacts with Rb and E2F1 during granulocytic differentiation (PMID:12947005)
• E2F1 is upregulated by TR3 orphan nuclear receptor in human prostate cancer cells (PMID:12947120)
• the Cyclin D1/E2F1 pathway may be involved in apoptotic death of bone marrow cells in myelodysplastic syndromes (PMID:12965081)
• E2F1 activity is repressed by BRG1, but this repression is blocked when BRG1 interacts with EVI1 (PMID:14555651)
• two E2F-binding sites play distinct roles in the regulation of E2F1 transcription by interacting with different sets of E2F members and cooperating with the contiguous repressor element (PMID:14576826)
• Here we show that the E2F1 binding domain of prohibitin has the potential to fold into a coiled-coil structure. (PMID:14637159)
• E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastoma (PMID:14645238)
• results establish that tumor necrosis factor alpha targets insulin-like growth factor-I induced E2F-transcription facor 1 synthesis, leading to inhibition of accumulation in cyclin A and hyperphosphorylation of RB protein (PMID:14681231)
• E2F1 transactivation is repressed by MdmX (PMID:14739777)
• Our results suggest that overexpression of E2F1, induced both by LOH at the RB locus and anomalous phosphorylation of the RB protein, is involved in the development of non-small cell lung carcinoma. (PMID:14997382)
• Results suggest that E2F1 plays a central role in signaling disturbances in the retinoblastoma growth control pathway and, by upregulation of Chk2 by Atm and Nbs1, may sensitize cells to undergo apoptosis. (PMID:15024084)
• The data suggest that E2F-1 overexpression plays a role in suppression of tumor, at least in part trough transcriptional regulation of FHIT and relevant activation of WWOX. (PMID:15044096)
• ErbB3-binding protein Ebp1 binding to E2F promoter elements and E2F-mediated transcription are regulated by heregulin (PMID:15073182)
• increased expression of the E2F1 gene might play a significant role in human thyroid carcinogenesis through derangement of the Rb-E2F signaling pathway (PMID:15118916)
• E2F1-dependent recruitment of Tip60 to chromatin occurred in late G(1) (PMID:15121871)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	e2f1	ENSDARG00000103868
mus_musculus	E2f1	ENSMUSG00000027490
rattus_norvegicus	E2f1	ENSRNOG00000072439
caenorhabditis_elegans		WBGENE00009899

Paralogs (7): E2F2 (ENSG00000007968), E2F3 (ENSG00000112242), E2F8 (ENSG00000129173), E2F5 (ENSG00000133740), E2F7 (ENSG00000165891), E2F6 (ENSG00000169016), E2F4 (ENSG00000205250)

Protein

Protein identifiers

Transcription factor E2F1 — Q01094 (reviewed: Q01094)

Alternative names: PBR3, Retinoblastoma-associated protein 1, Retinoblastoma-binding protein 3, pRB-binding protein E2F-1

All UniProt accessions (1): Q01094

UniProt curated annotations — full annotation on UniProt →

Function. Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5’-TTTC[CG]CGC-3’ found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters. Directly activates transcription of PEG10. Positively regulates transcription of RRP1B.

Subunit / interactions. Component of the DRTF1/E2F transcription factor complex. Forms heterodimers with DP family members. The E2F1 complex binds specifically hypophosphorylated RB1, the interaction represses E2F1-driven transcription. During the cell cycle, RB1 becomes phosphorylated in mid-to-late G1 phase, detaches from the DRTF1/E2F complex, rendering E2F transcriptionally active. Viral oncoproteins, notably E1A, T-antigen and HPV E7, are capable of sequestering RB1, thus releasing the active complex. Interacts with TRRAP, which probably mediates its interaction with histone acetyltransferase complexes, leading to transcription activation. Binds TOPBP1 and EAPP. Interacts with ARID3A. Interacts with TRIM28; the interaction inhibits E2F1 acetylation through recruiting HDAC1 and represses its transcriptional activity. Interaction with KAT2B; the interaction acetylates E2F1 enhancing its DNA-binding and transcriptional activity. Interacts with BIRC2/c-IAP1 (via BIR domains). The complex TFDP1:E2F1 interacts with CEBPA; the interaction prevents CEBPA binding to target genes promoters and represses its transcriptional activity. Interacts with RRP1B. Interacts with HCFC1. Interacts with KMT2E; the interaction is probably indirect and is mediated via HCFC1. Interacts with DCAF5 and L3MBTL3; the interaction requires methylation at Lys-185 and is necessary to target E2F1 for ubiquitination by the CRL4-DCAF5 E3 ubiquitin ligase complex. (Microbial infection) Interacts with human cytomegalovirus/HHV-5 protein UL123.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylated by CDK2 and cyclin A-CDK2 in the S-phase. Phosphorylation at Ser-364 by CHEK2 stabilizes E2F1 upon DNA damage and regulates its effect on transcription and apoptosis. Phosphorylation at Ser-403 by GSK3B promotes interaction with USP11, leading to its deubiquitination and stabilization. Ubiquitinated via ‘Lys-63’-linked ubiquitin, leading to its degradation. Deubiquitinated by USP11 following phosphorylation by GSK3B, promoting its stability. Acetylation stimulates DNA-binding. Enhanced under stress conditions such as DNA damage and inhibited by retinoblastoma protein RB1. Regulated by KAP1/TRIM28 which recruits HDAC1 to E2F1 resulting in deacetylation. Acetylated by P/CAF/KAT2B. Methylation at Lys-185 by SETD7 promotes E2F1 ubiquitin-dependent proteasomal degradation.

Activity regulation. BIRC2/c-IAP1 stimulates its transcriptional activity.

Similarity. Belongs to the E2F/DP family.

RefSeq proteins (1): NP_005216* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003316	E2F_WHTH_DNA-bd_dom	Domain
IPR015633	E2F	Family
IPR032198	E2F_CC-MB	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR037241	E2F-DP_heterodim	Homologous_superfamily

Pfam: PF02319, PF16421

UniProt features (51 total): region of interest 10, mutagenesis site 9, modified residue 8, strand 6, sequence variant 5, sequence conflict 4, helix 4, chain 1, DNA-binding region 1, short sequence motif 1, compositionally biased region 1, turn 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
6G0P	X-RAY DIFFRACTION	1.3
5M9O	X-RAY DIFFRACTION	1.45
6ULS	X-RAY DIFFRACTION	1.5
5M9N	X-RAY DIFFRACTION	1.95
1H24	X-RAY DIFFRACTION	2.5
2AZE	X-RAY DIFFRACTION	2.55
1O9K	X-RAY DIFFRACTION	2.6
9CB3	ELECTRON MICROSCOPY	3.47

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01094-F1	63.40	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 117, 120, 125, 185, 364, 375, 403, 433

Mutagenesis-validated functional residues (9):

Position	Phenotype
117	abolishes acetylation; when associated with r-120 and r-125.
120	abolishes acetylation; when associated with r-117 and r-125.
125	abolishes acetylation; when associated with r-117 and r-120.
132	abolishes interaction with and repression of cebpa and inhibition of adipogenesis.
185	abrogates methylation by setd7. loss of interaction with l3mbtl3. loss of ubiquitination by the crl4-dcaf5 e3 ubiquitin
364	abrogates in vitro phosphorylation by chek2 and chek2-dependent stabilization of e2f1 upon dna damage.
403	decreased phosphorylation by gsk3b, leading to abolished interaction with usp11 and subsequent deubiquitination.
411	no retinoblastoma protein binding. no effect on interaction with and repression of cebpa.
433	decreased phosphorylation by gsk3b.

Function

Pathways and Gene Ontology

Reactome pathways

17 pathways

ID	Pathway
R-HSA-111448	Activation of NOXA and translocation to mitochondria
R-HSA-113501	Inhibition of replication initiation of damaged DNA by RB1/E2F1
R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex
R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
R-HSA-139915	Activation of PUMA and translocation to mitochondria
R-HSA-1912408	Pre-NOTCH Transcription and Translation
R-HSA-2559580	Oxidative Stress Induced Senescence
R-HSA-2559585	Oncogene Induced Senescence
R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
R-HSA-68911	G2 Phase
R-HSA-69202	Cyclin E associated events during G1/S transition
R-HSA-69205	G1/S-Specific Transcription
R-HSA-69231	Cyclin D associated events in G1
R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry
R-HSA-8953750	Transcriptional Regulation by E2F6
R-HSA-9616222	Transcriptional regulation of granulopoiesis
R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)

MSigDB gene sets: 659 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_DN, GSE45365_NK_CELL_VS_CD11B_DC_UP, RNGTGGGC_UNKNOWN, E2F_Q4, REACTOME_INHIBITION_OF_REPLICATION_INITIATION_OF_DAMAGED_DNA_BY_RB1_E2F1, REACTOME_SIGNALING_BY_NOTCH, MODULE_52, E2F_Q4_01, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, REACTOME_G1_S_SPECIFIC_TRANSCRIPTION, HNF3ALPHA_Q6, PAX4_01, PID_TELOMERASE_PATHWAY, E2F4DP1_01

GO Biological Process (31): DNA damage checkpoint signaling (GO:0000077), negative regulation of transcription by RNA polymerase II (GO:0000122), DNA-templated transcription (GO:0006351), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), spermatogenesis (GO:0007283), intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630), positive regulation of gene expression (GO:0010628), quinolinate biosynthetic process (GO:0019805), forebrain development (GO:0030900), response to lipopolysaccharide (GO:0032496), positive regulation of apoptotic process (GO:0043065), anoikis (GO:0043276), negative regulation of DNA binding (GO:0043392), negative regulation of fat cell differentiation (GO:0045599), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of fibroblast proliferation (GO:0048146), mRNA stabilization (GO:0048255), positive regulation of glial cell proliferation (GO:0060252), negative regulation of fat cell proliferation (GO:0070345), cellular response to fatty acid (GO:0071398), cellular response to hypoxia (GO:0071456), cellular response to xenobiotic stimulus (GO:0071466), intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332), lens fiber cell apoptotic process (GO:1990086), cellular response to nerve growth factor stimulus (GO:1990090), regulation of G1/S transition of mitotic cell cycle (GO:2000045), apoptotic process (GO:0006915), regulation of cell cycle (GO:0051726)

GO Molecular Function (14): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), cis-regulatory region sequence-specific DNA binding (GO:0000987), DNA-binding transcription activator activity (GO:0001216), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein kinase binding (GO:0019901), sequence-specific DNA binding (GO:0043565), protein dimerization activity (GO:0046983), molecular adaptor activity (GO:0060090), DNA-binding transcription factor binding (GO:0140297), sequence-specific double-stranded DNA binding (GO:1990837), transcription cis-regulatory region binding (GO:0000976), protein binding (GO:0005515)

GO Cellular Component (10): nuclear chromosome (GO:0000228), chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), centrosome (GO:0005813), protein-containing complex (GO:0032991), Rb-E2F complex (GO:0035189), RNA polymerase II transcription regulator complex (GO:0090575), transcription regulator complex (GO:0005667)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
Activation of BH3-only proteins	2
G0 and Early G1	2
Cellular Senescence	2
G1/S Transition	2
E2F mediated regulation of DNA replication	1
Pre-NOTCH Expression and Processing	1
TP53 Regulates Transcription of Cell Cycle Genes	1
Mitotic G2-G2/M phases	1
G1 Phase	1
S Phase	1
Generic Transcription Pathway	1
Developmental Biology	1
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	4
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
DNA-templated transcription	3
transcription cis-regulatory region binding	3
cellular anatomical structure	3
gene expression	2
regulation of gene expression	2
apoptotic process	2
DNA binding	2
positive regulation of DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-binding transcription factor activity	2
binding	2
chromosome	2
nuclear lumen	2
DNA integrity checkpoint signaling	1
signal transduction in response to DNA damage	1
negative regulation of DNA-templated transcription	1
RNA biosynthetic process	1
regulation of RNA biosynthetic process	1
developmental process involved in reproduction	1
male gamete generation	1
DNA damage response	1
intrinsic apoptotic signaling pathway	1
positive regulation of macromolecule biosynthetic process	1
dicarboxylic acid biosynthetic process	1
quinolinate metabolic process	1
pyridine-containing compound biosynthetic process	1
brain development	1
anatomical structure development	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
negative regulation of binding	1
regulation of DNA binding	1
fat cell differentiation	1
negative regulation of cell differentiation	1

Protein interactions and networks

STRING

4508 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
E2F1	RB1	P06400	996
E2F1	FOXO3	O43524	995
E2F1	TFDP1	Q14186	994
E2F1	HDAC1	Q13547	992
E2F1	MYC	P01106	990
E2F1	CCNA2	P20248	989
E2F1	CCNA1	P78396	985
E2F1	MDM2	Q00987	981
E2F1	TP53	P04637	974
E2F1	CDKN1A	P38936	947
E2F1	TOPBP1	Q92547	946
E2F1	DNMT1	P26358	945
E2F1	NDN	Q99608	937
E2F1	CDKN2A	P42771	921
E2F1	HCFC1	P51610	919

IntAct

186 interactions, top by confidence:

A	B	Type	Score
RB1	E2F1	psi-mi:“MI:0915”(physical association)	0.980
E2F1	RB1	psi-mi:“MI:0407”(direct interaction)	0.980
E2F1	RB1	psi-mi:“MI:0915”(physical association)	0.980
E2F1	RB1	psi-mi:“MI:0914”(association)	0.980
RB1	E2F1	psi-mi:“MI:0407”(direct interaction)	0.980

BioGRID (492): E2F1 (Reconstituted Complex), RB1 (Affinity Capture-Western), E2F1 (Affinity Capture-RNA), E2F1 (Affinity Capture-RNA), E2F1 (Two-hybrid), E2F1 (Affinity Capture-Western), KAT2B (Affinity Capture-Western), E2F1 (Affinity Capture-Western), CREBBP (Reconstituted Complex), E2F1 (Affinity Capture-Western), E2F1 (Affinity Capture-Western), E2F1 (Affinity Capture-Western), E2F1 (Affinity Capture-Western), E2F1 (Affinity Capture-Western), TFDP1 (Affinity Capture-Western)

ESM2 similar proteins: A0JMD2, A5D7E9, A6NMN3, A7XW16, F1QDF8, F1RDM5, O00716, O09139, O35261, O35668, O42367, O43151, O54968, P14607, P59054, P59598, P97691, Q00175, Q01094, Q08050, Q14209, Q14494, Q16254, Q4V8F1, Q5DU28, Q5NUA6, Q5RA25, Q5W1J6, Q5ZL67, Q60664, Q60795, Q61321, Q61501, Q61985, Q63449, Q66IG8, Q6DJE5, Q6JPI3, Q76N89, Q7TS75

Diamond homologs: A0AVK6, A5HWA8, D4A4D7, E1BE02, E1BKK0, F1LMN3, F1QZ88, F6YVB9, F7EA39, O00716, O35261, O54917, O75461, P56931, Q01094, Q08DY6, Q14209, Q15329, Q16254, Q20619, Q27368, Q58FA4, Q5RIX9, Q61501, Q61502, Q62814, Q6DE14, Q6S7F2, Q8LSZ4, Q8R0K9, Q8RWL0, Q90977, Q96AV8, Q9FNY0, Q9FV70, Q9FV71, Q9LFQ9, O09139, O77051

SIGNOR signaling

72 interactions.

A	Effect	B	Mechanism
CHEK2	“up-regulates quantity by stabilization”	E2F1	phosphorylation
MAPK3	up-regulates	E2F1	phosphorylation
CDK8	down-regulates	E2F1	phosphorylation
HES1	“down-regulates quantity by repression”	E2F1	“transcriptional regulation”
HES6	“up-regulates quantity by expression”	E2F1	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	ATM	“transcriptional regulation”
E2F1	up-regulates	HDAC1	binding
E2F1	“form complex”	SMAD7/HDAC1/E2F-1	binding
HDAC3	up-regulates	E2F1	binding
E2F1	up-regulates	PPARG	“transcriptional regulation”
ERK1/2	“up-regulates activity”	E2F1	phosphorylation
E2F1	“up-regulates quantity by expression”	CDC25A	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	CyclinE/CDK2	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	CCNE1	“transcriptional regulation”
E2F1	up-regulates	G1/S_transition
E2F1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	BBC3	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	HIC1	“transcriptional regulation”
E2F1	“down-regulates quantity by repression”	HSPA5	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	LRBA	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	MCPH1	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	ELF4	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	RASGRP1	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	RASGEF1B	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	RRM1	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	DHFR	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 65 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	5	61.0×	8e-07
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	5	57.8×	1e-06
Transcription of E2F targets under negative control by DREAM complex	5	52.3×	2e-06
Oncogene Induced Senescence	8	51.7×	1e-09
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	6	42.5×	4e-07
G0 and Early G1	5	42.2×	4e-06
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	7	41.5×	3e-08
G1/S-Specific Transcription	6	41.2×	4e-07

GO biological processes:

GO term	Partners	Fold	FDR
cellular response to insulin stimulus	6	16.5×	2e-04
chromatin remodeling	10	11.8×	3e-06
negative regulation of cell growth	5	11.6×	3e-03
regulation of cell cycle	9	10.8×	2e-05
negative regulation of gene expression	7	7.8×	2e-03
DNA damage response	8	6.9×	1e-03
transcription by RNA polymerase II	6	6.8×	7e-03
positive regulation of apoptotic process	7	6.4×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	35
Likely benign	8
Benign	9

Top pathogenic / likely-pathogenic (0)

SpliceAI

1707 predictions. Top by Δscore:

Variant	Effect	Δscore
10:47353372:G:GC	acceptor_gain	1.0000
10:47353514:C:CT	donor_loss	1.0000
10:47353515:A:AT	donor_loss	1.0000
10:47353516:GAC:G	donor_loss	1.0000
10:47353517:TGAC:T	donor_loss	1.0000
10:47355518:ACC:A	donor_loss	1.0000
10:47355520:GTA:G	donor_loss	1.0000
10:47355521:CGTA:C	donor_loss	1.0000
20:33676980:C:CC	acceptor_gain	1.0000
20:33677102:CACC:C	donor_loss	1.0000
20:33677327:AGTT:A	acceptor_gain	1.0000
20:33677420:TCTCA:T	donor_loss	1.0000
20:33677421:CTCA:C	donor_loss	1.0000
20:33677422:TCAC:T	donor_loss	1.0000
20:33677423:CA:C	donor_loss	1.0000
20:33677424:A:T	donor_loss	1.0000
20:33677425:C:CT	donor_loss	1.0000
20:33678216:T:TA	donor_gain	1.0000
20:33678235:G:C	donor_gain	1.0000
20:33678349:TGCCC:T	acceptor_gain	1.0000
20:33678350:GCCC:G	acceptor_gain	1.0000
20:33678351:CCC:C	acceptor_gain	1.0000
20:33678351:CCCC:C	acceptor_gain	1.0000
20:33678352:CC:C	acceptor_gain	1.0000
20:33678352:CCCTG:C	acceptor_gain	1.0000
20:33678353:CCTG:C	acceptor_gain	1.0000
20:33678354:C:CC	acceptor_gain	1.0000
20:33678354:C:CG	acceptor_loss	1.0000
20:33678355:T:A	acceptor_loss	1.0000
20:33679753:A:AC	donor_gain	1.0000

AlphaMissense

2804 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:33679764:A:T	I188N	1.000
20:33679769:G:C	N186K	1.000
20:33679769:G:T	N186K	1.000
20:33679772:C:A	K185N	1.000
20:33679772:C:G	K185N	1.000
20:33679774:T:C	K185E	1.000
20:33679781:C:A	K182N	1.000
20:33679781:C:G	K182N	1.000
20:33679783:T:C	K182E	1.000
20:33679788:A:T	I180N	1.000
20:33679791:A:G	L179P	1.000
20:33679801:C:G	G176R	1.000
20:33679806:A:G	L174P	1.000
20:33679806:A:T	L174H	1.000
20:33679809:A:T	V173D	1.000
20:33679811:G:C	N172K	1.000
20:33679811:G:T	N172K	1.000
20:33679813:T:C	N172D	1.000
20:33679818:A:C	I170S	1.000
20:33679818:A:T	I170N	1.000
20:33679820:G:C	D169E	1.000
20:33679820:G:T	D169E	1.000
20:33679821:T:A	D169V	1.000
20:33679821:T:C	D169G	1.000
20:33679821:T:G	D169A	1.000
20:33679822:C:A	D169Y	1.000
20:33679822:C:G	D169H	1.000
20:33679822:C:T	D169N	1.000
20:33679824:T:C	Y168C	1.000
20:33679825:A:G	Y168H	1.000

dbSNP variants (sampled 300 via entrez): RS1000130244 (20:33684356 C>T), RS1000295629 (20:33678601 T>C), RS1000518535 (20:33684056 C>G,T), RS1000962550 (20:33676496 C>T), RS1001002474 (20:33677017 C>T), RS1001124749 (20:33682922 T>C), RS1001462616 (20:33685678 C>T), RS1001505758 (20:33683354 G>C), RS1001567608 (20:33679398 G>T), RS1001619912 (20:33679093 T>C), RS1001726041 (20:33685896 C>T), RS1001773214 (20:33685431 T>C), RS1001794744 (20:33684443 C>A,G), RS1002056610 (20:33684687 T>C), RS1002205824 (20:33685673 G>A,C)

Disease associations

OMIM: gene MIM:189971 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), long QT syndrome (MONDO:0002442)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006979_538	Heel bone mineral density	1.000000e-19
GCST008839_103	Height	5.000000e-13
GCST012226_838	Waist circumference adjusted for body mass index	4.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4382 (SINGLE PROTEIN), CHEMBL4630726 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

179 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases reaction, increases expression, decreases expression, affects expression, affects reaction (+1 more)	7
bisphenol A	affects expression, increases expression, affects cotreatment	6
Arsenic Trioxide	affects binding, decreases reaction, increases reaction, decreases expression, increases expression (+1 more)	6
Benzo(a)pyrene	increases expression, increases methylation, increases reaction, decreases reaction, affects activity (+1 more)	6
Estradiol	decreases reaction, increases expression, affects reaction, affects expression, affects binding (+1 more)	6
Tretinoin	decreases reaction, increases expression, decreases expression	6
Cannabidiol	decreases expression, increases expression, affects cotreatment	5
Doxorubicin	affects expression, affects binding, decreases reaction, increases expression, increases reaction (+3 more)	4
Cadmium Chloride	decreases expression, increases expression, decreases reaction	4
methylselenic acid	affects expression, affects binding, increases reaction, decreases expression	3
(+)-JQ1 compound	affects cotreatment, decreases expression, decreases activity	3
Troglitazone	affects cotreatment, decreases expression	3
Aspirin	affects cotreatment, affects binding, decreases reaction, decreases expression	3
Cisplatin	decreases expression, increases acetylation, increases expression	3
Copper	affects binding, decreases expression, increases expression	3
Nicotine	decreases reaction, increases expression, affects binding, increases reaction	3
Valproic Acid	affects expression, increases expression, increases methylation	3
zinc chromate	decreases expression, affects localization, affects reaction, increases abundance	2
cadmium acetate	affects binding, increases reaction, decreases activity, decreases expression, affects localization	2
hydroquinone	increases expression, increases reaction	2
chromium hexavalent ion	affects localization, affects reaction, increases abundance, decreases expression	2
alvocidib	increases expression, increases response to substance, decreases expression	2
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	2
Gefitinib	decreases expression	2
Acetaminophen	increases expression	2
Arsenic	decreases expression, increases expression, affects reaction	2
Chelating Agents	affects binding, decreases expression, increases expression	2
Oxygen	affects cotreatment, decreases expression	2
Quercetin	increases expression	2
Tamoxifen	increases expression, decreases expression, affects binding, increases reaction	2

ChEMBL screening assays

12 unique, capped per target: 12 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2445129	Binding	Induction of E2F1 ubiquitination in human A549 cells at 0.1 uM after 8 hrs by immunoprecipitation and Western blotting analysis	Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells. — ACS Med Chem Lett

Cellosaurus cell lines

13 cell lines: 8 cancer cell line, 3 embryonic stem cell, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1B8	SEES3-1V human E2F1, clone1	Embryonic stem cell	Male
CVCL_A1B9	SEES3-1V human E2F1, clone2	Embryonic stem cell	Male
CVCL_A1C0	SEES3-1V human E2F1, clone3	Embryonic stem cell	Male
CVCL_AW19	K562 eGFP-E2F1	Cancer cell line	Female
CVCL_B1AS	Abcam HEK293 E2F1 KO	Transformed cell line	Female
CVCL_B6FC	HepZ	Transformed cell line	Sex unspecified
CVCL_B8EY	Abcam HCT 116 E2F1 KO	Cancer cell line	Male
CVCL_B8V1	Abcam MCF-7 E2F1 KO	Cancer cell line	Female
CVCL_B9H6	Abcam A-549 E2F1 KO	Cancer cell line	Male
CVCL_HA20	MCF-7/E2F1	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer